Search results for " mutation"

showing 10 items of 1212 documents

Image of the Month—Quiz Case

2008

medicine.medical_specialtyMutationbusiness.industrymedicine.medical_treatmentCancerJuvenile Polyposismedicine.disease_causemedicine.diseaseGastroenterologyGermlineSurgeryEsophagus surgeryEndocrinologyGermline mutationInternal medicinemedicineSurgeryGastrectomybusinessArchives of Surgery
researchProduct

2015

Several point mutations have been identified in human aquaporins, but their effects on the function of the respective aquaporins are mostly enigmatic. We analyzed the impact of the aquaporin 2 mutation V71M, which causes nephrogenic diabetes insipidus in humans, on aquaporin structure and activity, using the bacterial aquaglyceroporin GlpF as a model. Importantly, the sequence and structure around the V71M mutation is highly conserved between aquaporin 2 and GlpF. The V71M mutation neither impairs substrate flux nor oligomerization of the aquaglyceroporin. Therefore, the human aquaporin 2 mutant V71M is most likely active, but cellular trafficking is probably impaired.

medicine.medical_specialtyMutationurogenital systemPoint mutationMutantAquaporinBiologymedicine.disease_causeNephrogenic diabetes insipidusmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyCell biologyEndocrinologyAquaporin 2Internal medicineArginine vasopressin receptor 2medicineProtein oligomerizationFEBS Open Bio
researchProduct

Cowden's syndrome diagnosed through oral lesions : a case report

2021

Cowden's syndrome (CS), also known as multiple hamartoma syndrome, is a rare autosomal dominant genodermatosis first described in 1963. It has a high penetrance in both sexes and variable phenotypes. Its origin is a PTEN (phosphatase and tensin homologue) gene mutation and affects multiple organs of endodermal, ectodermal, and mesodermal origin, resulting in the development of hamartomatous mucocutaneus lesions and an increased risk for malignancies in breast, thyroid, endometrium, kidney, colon, rectum, among other organs. The diagnosis of CS is based mainly on clinical findings and oral cavity manifestations are frequent, occurring in 80-90% of patients. This include oral and labial papil…

medicine.medical_specialtyOral Medicine and Pathologybiologybusiness.industryThyroidGenodermatosisRectumMultiple hamartoma syndromeCase ReportGene mutationmedicine.diseaseDermatologyPenetrancestomatognathic diseasesmedicine.anatomical_structuremedicinebiology.proteinPTENmedia_common.cataloged_instancebusinessGeneral DentistryDental surgeonUNESCO:CIENCIAS MÉDICASmedia_common
researchProduct

P03-010-B - A novel mutation in MEFV gene is not enough

2013

Genotype-phenotype correlation is still challenging in FMF patients especially when the disease is part of a complex autoinflammatory disease.

medicine.medical_specialtyPediatricsbusiness.industryDiseaseBioinformaticsMEFVRheumatologyRheumatologyInternal medicineMeeting AbstractPediatrics Perinatology and Child HealthImmunology and AllergyMedicinePediatrics Perinatology and Child HealthAutoinflammatory diseasebusinessNovel mutationGenePediatric Rheumatology
researchProduct

A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone

2018

Key Teaching Points • Despite proven catecholaminergic polymorphic ventricular tachycardia (CPVT) with pathogen RyR2 mutation and recurrent syncope, patients could have a favorable long-term outcome over 35 years under treatment. • Propafenone could be effective for treatment of patients with CPVT. • The beneficial effect of the monotherapy with propafenone in our patient may result from the combined antiarrhythmic effect of this drug with Na+ channel blockade and beta blocker capabilities.

medicine.medical_specialtyPolymorphic premature ventricular beatsmedicine.drug_classCase ReportPropafenone030204 cardiovascular system & hematologyCatecholaminergic polymorphic ventricular tachycardiaRyanodine receptor 203 medical and health sciences0302 clinical medicinePropafenoneInternal medicineMedicineEffective treatment030212 general & internal medicineExercise-induced syncopeBeta blockerbusiness.industrymedicine.diseaseBlockadeExercise-induced syncopeCatecholaminergic polymorphic ventricular tachycardiacardiovascular systemCardiologyAntiarrhythmic effectCardiology and Cardiovascular MedicinebusinessRyanodine receptor mutationmedicine.drugHeartRhythm Case Reports
researchProduct

Tamoxifen, a Trigger Factor of Hereditary Angioedema with Normal C1-INH with a Specific Mutation in the F12 Gene (HAE-FXII)

2016

medicine.medical_specialtyTrigger factorSpecific mutationbusiness.industryImmunologymedicine.diseaseEndocrinologyInternal medicineHereditary angioedemamedicineCancer researchImmunology and AllergybusinessGeneTamoxifenmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Rando…

2012

Abstract Abstract 412 Background: A large proportion of patients are currently not eligible for genotype-adapted strategies in acute myeloid leukemia (AML), in particular those lacking specific genetic aberrations such as PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, NPM1 or activating FLT3 mutations. This subgroup of patients accounts for about one-third of all AML patients and mainly includes the large group of AML with myelodysplasia-related changes, AML with recurrent cytogenetic abnormalities [inv(3) or t(3;3), t(9;11), t(v;11q23)] and cytogenetically normal AML (CN-AML) with wild-type NPM1 and FLT3. Prognosis in this subgroup of patients is generally poor. Azacitidine has been shown to be acti…

medicine.medical_specialtybusiness.industryImmunologyAzacitidineInduction chemotherapyCell BiologyHematologyGene mutationBiochemistryGastroenterology3. Good healthSurgeryTransplantation03 medical and health sciences0302 clinical medicineMaintenance therapy030220 oncology & carcinogenesisInternal medicinemedicineCytarabineIdarubicinbusinessEtoposide030215 immunologymedicine.drugBlood
researchProduct

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionImproved survivalCell BiologyHematologyNewly diagnosedPlaceboBiochemistryConsolidation therapy03 medical and health sciencesNPM1 Mutationchemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisFamily medicineMedicineIn patientMidostaurinbusiness030215 immunologyBlood
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct

Mutations in the NKX2.5 Gene and the PAX8 Promoter in a Girl with Thyroid Dysgenesis

2011

Screening of the known candidate genes involved in thyroid organogenesis has revealed mutations in a small subset of patients with congenital hypothyroidism due to thyroid dysgenesis (TD).We studied a girl with TD who had mutations in two transcription factors involved in thyroid development.Sequencing analysis of candidate genes involved in thyroid gland development revealed a new paternally inherited heterozygous mutation in the NKX2.5 gene (S265R) and a new maternally inherited heterozygous mutation in the PAX8 promoter region (-456CT). Both parents and a brother, who was also heterozygous for both mutations, were phenotypically normal. Immunofluorescence microscopy showed a correct nucl…

medicine.medical_specialtyendocrine systemendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryBiologyGene mutationDominant-Negative Mutationmedicine.disease_causeBiochemistryThyroid dysgenesisPAX8 Transcription FactorEndocrinologyInternal medicinemedicineCongenital HypothyroidismHumansPaired Box Transcription FactorsPromoter Regions GeneticGeneticsHomeodomain ProteinsMutationBiochemistry (medical)ThyroidJCEM Online: Brief Reportsmedicine.diseaseCongenital hypothyroidismmedicine.anatomical_structureEndocrinologyMutationThyroid DysgenesisCancer researchHomeobox Protein Nkx-2.5ThyroglobulinFemalePAX8Transcription Factors
researchProduct